MIRATI THERAPEUTICS INC's ticker is MRTX and the CUSIP is 60468T105. A total of 228 filers reported holding MIRATI THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 1.34 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $61,410,191 | +20.6% | 1,409,784 | 0.0% | 0.35% | +20.0% |
Q2 2023 | $50,935,496 | -2.8% | 1,409,784 | 0.0% | 0.30% | +3.5% |
Q1 2023 | $52,415,769 | -17.9% | 1,409,784 | 0.0% | 0.28% | -25.8% |
Q4 2022 | $63,877,313 | -35.1% | 1,409,784 | 0.0% | 0.38% | -40.5% |
Q3 2022 | $98,459,000 | +4.0% | 1,409,784 | 0.0% | 0.64% | +20.1% |
Q2 2022 | $94,639,000 | -18.4% | 1,409,784 | 0.0% | 0.54% | -19.4% |
Q1 2022 | $115,912,000 | -43.9% | 1,409,784 | 0.0% | 0.67% | -33.8% |
Q4 2021 | $206,801,000 | -17.1% | 1,409,784 | 0.0% | 1.01% | -8.1% |
Q3 2021 | $249,405,000 | +9.5% | 1,409,784 | 0.0% | 1.10% | +9.5% |
Q2 2021 | $227,722,000 | -5.7% | 1,409,784 | 0.0% | 1.00% | -4.5% |
Q1 2021 | $241,496,000 | -22.0% | 1,409,784 | 0.0% | 1.05% | -10.3% |
Q4 2020 | $309,645,000 | +32.3% | 1,409,784 | 0.0% | 1.17% | +24.8% |
Q3 2020 | $234,095,000 | +45.4% | 1,409,784 | 0.0% | 0.94% | +31.7% |
Q2 2020 | $160,955,000 | +48.5% | 1,409,784 | 0.0% | 0.71% | +6.4% |
Q1 2020 | $108,370,000 | -35.7% | 1,409,784 | +7.8% | 0.67% | -25.6% |
Q4 2019 | $168,448,000 | +65.4% | 1,307,220 | 0.0% | 0.90% | +29.3% |
Q3 2019 | $101,846,000 | -60.7% | 1,307,220 | -48.0% | 0.69% | -60.6% |
Q2 2019 | $258,887,000 | +40.5% | 2,513,462 | 0.0% | 1.76% | +49.2% |
Q1 2019 | $184,237,000 | +72.8% | 2,513,462 | 0.0% | 1.18% | +35.1% |
Q4 2018 | $106,621,000 | -9.9% | 2,513,462 | 0.0% | 0.87% | +11.9% |
Q3 2018 | $118,384,000 | -4.5% | 2,513,462 | 0.0% | 0.78% | -16.2% |
Q2 2018 | $123,914,000 | +58.3% | 2,513,462 | -1.4% | 0.93% | +40.4% |
Q1 2018 | $78,268,000 | +68.2% | 2,549,461 | 0.0% | 0.66% | +64.5% |
Q4 2017 | $46,528,000 | +75.3% | 2,549,461 | +12.4% | 0.40% | +87.4% |
Q3 2017 | $26,549,000 | +220.5% | 2,269,198 | 0.0% | 0.22% | +198.6% |
Q2 2017 | $8,283,000 | -29.8% | 2,269,198 | 0.0% | 0.07% | -25.8% |
Q1 2017 | $11,800,000 | +9.5% | 2,269,198 | 0.0% | 0.10% | -8.5% |
Q4 2016 | $10,779,000 | -28.1% | 2,269,198 | 0.0% | 0.11% | -22.1% |
Q3 2016 | $14,999,000 | +21.1% | 2,269,198 | 0.0% | 0.14% | +4.6% |
Q2 2016 | $12,390,000 | -82.3% | 2,269,198 | -30.6% | 0.13% | -82.4% |
Q1 2016 | $69,947,000 | -25.1% | 3,268,556 | +10.6% | 0.74% | -4.7% |
Q4 2015 | $93,380,000 | -8.2% | 2,955,074 | 0.0% | 0.77% | -17.7% |
Q3 2015 | $101,714,000 | +15.2% | 2,955,074 | +5.3% | 0.94% | +21.4% |
Q2 2015 | $88,276,000 | +7.3% | 2,805,074 | 0.0% | 0.77% | +13.2% |
Q1 2015 | $82,245,000 | +86.6% | 2,805,074 | +17.9% | 0.68% | +52.0% |
Q4 2014 | $44,079,000 | +5.8% | 2,380,074 | 0.0% | 0.45% | -14.3% |
Q3 2014 | $41,675,000 | -12.4% | 2,380,074 | 0.0% | 0.52% | -9.9% |
Q2 2014 | $47,601,000 | +4.9% | 2,380,074 | 0.0% | 0.58% | +1.0% |
Q1 2014 | $45,388,000 | +14.7% | 2,380,074 | 0.0% | 0.58% | +3.4% |
Q4 2013 | $39,581,000 | +31.9% | 2,380,074 | +20.2% | 0.56% | +31.0% |
Q3 2013 | $29,998,000 | – | 1,980,074 | – | 0.43% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aviva Holdings Ltd. | 3,135,966 | $136,602,679 | 87.83% |
EcoR1 Capital, LLC | 5,748,399 | $250,400,260 | 8.45% |
Boxer Capital, LLC | 3,201,440 | $139,454,726 | 7.42% |
RTW INVESTMENTS, LP | 6,768,514 | $294,836,470 | 6.22% |
Paradigm Biocapital Advisors LP | 1,668,116 | $72,663,133 | 4.93% |
Avoro Capital Advisors LLC | 6,666,666 | $290,399,971 | 4.53% |
Octagon Capital Advisors LP | 655,051 | $28,534,022 | 4.38% |
Artal Group S.A. | 2,024,226 | $88,175 | 3.78% |
Ally Bridge Group (NY) LLC | 70,283 | $3,061,527 | 3.59% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 216,000 | $9,404,640 | 3.17% |